更正：安罗替尼联合免疫检查点抑制剂治疗二线及后续广泛期小细胞肺癌的疗效和安全性分析。

IF 2 4区医学 Q3 ONCOLOGY

Neoplasma Pub Date : 2024-10-01 DOI:10.4149/neo_2024_231104N572COR

Xixi Ying, Zheng Shi, Rongjun Shao, Guangxian You, Zhengbo Song

{"title":"更正：安罗替尼联合免疫检查点抑制剂治疗二线及后续广泛期小细胞肺癌的疗效和安全性分析。","authors":"Xixi Ying, Zheng Shi, Rongjun Shao, Guangxian You, Zhengbo Song","doi":"10.4149/neo_2024_231104N572COR","DOIUrl":null,"url":null,"abstract":"Due to the delayed delivery of the request for a correction and the requirement from the Office of Zhejiang Chinese Medical University to standardize the institution's English translation, the editorial department of NEOPLASMA has issued a correction in response to the author's signed request: The affiliation of the first author has been changed from \"Graduate School of Zhejiang University of Traditional Chinese Medicine\" to \"Graduate School, Zhejiang Chinese Medical University.\"","PeriodicalId":19266,"journal":{"name":"Neoplasma","volume":"71 5","pages":"509"},"PeriodicalIF":2.0000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Correction: Efficacy and safety analysis of anlotinib in combination with immune checkpoint inhibitors for second-line and subsequent extensive-stage small-cell lung cancer.\",\"authors\":\"Xixi Ying, Zheng Shi, Rongjun Shao, Guangxian You, Zhengbo Song\",\"doi\":\"10.4149/neo_2024_231104N572COR\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Due to the delayed delivery of the request for a correction and the requirement from the Office of Zhejiang Chinese Medical University to standardize the institution's English translation, the editorial department of NEOPLASMA has issued a correction in response to the author's signed request: The affiliation of the first author has been changed from \\\"Graduate School of Zhejiang University of Traditional Chinese Medicine\\\" to \\\"Graduate School, Zhejiang Chinese Medical University.\\\"\",\"PeriodicalId\":19266,\"journal\":{\"name\":\"Neoplasma\",\"volume\":\"71 5\",\"pages\":\"509\"},\"PeriodicalIF\":2.0000,\"publicationDate\":\"2024-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Neoplasma\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.4149/neo_2024_231104N572COR\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neoplasma","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.4149/neo_2024_231104N572COR","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

由于更正请求迟迟未能送达，且浙江中医药大学办公室要求规范该校英文译文，《NEOPLASMA》编辑部根据作者署名要求进行了更正：第一作者单位由 "浙江中医药大学研究生院 "改为 "浙江中医药大学研究生院"。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Correction: Efficacy and safety analysis of anlotinib in combination with immune checkpoint inhibitors for second-line and subsequent extensive-stage small-cell lung cancer.

Due to the delayed delivery of the request for a correction and the requirement from the Office of Zhejiang Chinese Medical University to standardize the institution's English translation, the editorial department of NEOPLASMA has issued a correction in response to the author's signed request: The affiliation of the first author has been changed from "Graduate School of Zhejiang University of Traditional Chinese Medicine" to "Graduate School, Zhejiang Chinese Medical University."

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊